anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Fragmentation of health care across systems can contribute to mistakes in prescribing and filling medications among patients treated for myocardial infarction (MI). We sought to compare omissions, duplications, and delays in outpatient medications used for secondary prevention among veterans treated for MI at Veterans Affairs (VA) versus non-VA hospitals.
METHODS: We utilized national VA and Centers for Medicare and Medicaid Services data (2012-2018) to identify veterans 65 years or older hospitalized for MI and measured the use of outpatient medications for secondary prevention in the 30 days after MI among those treated at VA versus non-VA hospitals.
RESULTS: A total of 118,456 veterans experiencing MI were included; of which 102,209 were hospitalized at non-VA hospitals. An omission in any medication class occurred more frequently among veterans treated at non-VA versus VA hospitals (82.8% vs 67.8%, P < 0.001). In multivariable modeling, the odds of omissions in any medication class were higher among those treated at non-VA versus VA hospitals (odds ratio: 3.04; 95% CI: 2.88-3.20). Duplications occurred more frequently in veterans treated at non-VA versus VA hospitals: 1.9% versus 1.6% had 1 or more for non-VA versus VA hospitals ( P < 0.001). Veterans treated at non-VA hospitals were more likely to have delays of 3 days or more in prescription fills after hospital discharge (88.4% vs 70.6% across all classes, P < 0.001).
CONCLUSIONS: Omissions, duplications, and delays in outpatient prescribing of secondary prevention medications were more common among 118,456 veterans treated at non-VA versus VA hospitals for MI. Interventions aimed at improving care transitions and optimizing medication use among veterans treated at non-VA hospitals should be implemented.
The invention relates to polynucleotide transfection (e.g. of pDNA or siRNA), and in particular, the use of polyplexes (complexes of a polynucleotide and a reducible (disulfide) polymer) as delivery vehicles. Compositions of the invention contain a reducing agent, such as glutathione (GSH) or N-acetyl cysteine (NAC). These are able to reduce, and so break, S- S bonds in the reducible disulfide polymer formed form polymerisation of thiol-containing monomers. This can result in the release of the polynucleotide (e.g. pDNA or siRNA). The reducible (disulfide) polymer is preferably formed from constituent monomer(s) units having a thiol group at each end, and a middle repeating section or unit of a polyamine, such as a spermine molecule.
School counsellors in South Korea face significant emotional exhaustion due to their challenging occupational environment. Previous studies have shown that cognitive reappraisal (CR) reduces emotional exhaustion, whereas expressive suppression (ES) increases it. However, these findings predominantly rely on trait questionnaires within cross-sectional approaches, overlooking the dynamic nature of emotion regulation (ER) strategy selection. Individuals may choose strategies that deviate from their general tendencies based on situational demands. There is limited empirical knowledge regarding the interaction between trait and state regulation strategies and their influence on exhaustion. Utilizing the strategy-situation fit hypothesis, this study examines the context-specific effects of ER strategies, considering both situational contexts and individual response tendencies. A multilevel analysis was performed to examine the influence of state and trait ER strategies on daily emotional exhaustion. A daily diary study was conducted for 5 days with 111 Korean school counsellors. Daily CR was associated with lower daily exhaustion and daily ES predicted higher daily exhaustion. Contrastingly, none of the trait ER strategies had an impact on daily exhaustion, but the trait level of both strategies significantly moderated the relationship between daily CR and exhaustion. The positive impact of daily CR was more pronounced in school counsellors who often utilized suppression strategies, and this impact was also evident in trait reappraisal. Re-evaluating daily emotions instead of suppressing them may assist in coping with emotional exhaustion caused by work. The effectiveness of these strategies may vary based on an individual's inclination to regulate emotions as state and trait. ER may aid in implementing preventive interventions for school counsellors experiencing emotional exhaustion.
This group will consist of up to 60 people who are on an extended infusing cycle of greater than 30 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week for a blood draw to measure Natalizumab concentration and other biomarkers during their extended cycle at Week 2, and Week 4, for a total of 3 study visits.
Understanding the metastatic cascade is critical for the treatment and prevention of cancer-related death. Within a tumor, immune cells have the capacity to fuse with tumor cells to generate tumor-immune hybrid cells (THCs). THCs are hypothesized to be a subset of cancer cells with the capacity to enter circulation as circulating hybrid cells (CHC) and seed metastases. To understand the mechanism of THC metastasis, we investigated CHCs in peripheral blood from patients with stage IV colorectal cancer (CRC), as well as THCs in tissues of primary colorectal cancers and their liver metastasis sites using immunofluorescence, spatial proteomic, spatial transcriptomic, molecular classification, and molecular pathway analyses. Our findings indicated a high prevalence of CHCs and THCs in patients with stage IV CRC. THCs expressed CTLA4 in primary CRC lesions and correlated with upregulation of CD68, CD4, and HLA-DR in metastatic liver lesions, which is found in the consensus molecular subtype (CMS) 1 of primary CRC tissue. Pathway analysis of these genes suggested that THCs are associated with neutrophils due to upregulation of neutrophil extracellular trap signaling (NET) and neutrophil degranulation pathways. These data provide molecular pathways for the formation of THCs suggesting fusion with neutrophils, which may facilitate extravasation and metastatic seeding.
PURPOSE: To obtain a cytostatic agent excellent in inhibitory effects on cells, useful for treating especially a solid tumor, containing a titanocene derivative as an active ingredient. CONSTITUTION: This cytostatic agent contains at least one titanocene derivative of formula I [A is a ligand of N<=C-R (R is a 1-6C alkyl) or X-Ar (X is O, S or selenium; Ar is a halogen or a phenyl substitutable with NO2 with the proviso that Ar is a substituted phenyl when X is S); B is a halide anion, the same as the ligand A or A and B form a group of formula II, etc.; Y is an anion in which (a) anions exist when a titanium complex has a positive charge]. The compound of formula I is blended with an excipient, a diluent, an auxiliary, etc., and pharmaceutically manufactured by a conventional procedure to give the objective substance. The substance can be prepared into a dosage form such as tablet, capsule, granule, powder, solution, suspension, suppository, etc. The content of the titanocene derivative of formula I is 0.01-95wt.% in a preparation.
BACKGROUND: Chronic rhinosinusitis (CRS) is a prevalent upper respiratory condition that manifests in two primary subtypes: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). While previous studies indicate a correlation between air pollution and CRS, the role of genetic predisposition in this relationship remains largely unexplored. We hypothesized that higher air pollution exposure would lead to the development of CRS, and that genetic susceptibility might modify this association.
METHODS: This cohort study involving 367,298 adult participants from the UK Biobank, followed from March 2006 to October 2021. Air pollution metrics were estimated at residential locations using land-use regression models. Cox proportional hazard models were employed to explore the associations between air pollution exposure and CRS, CRSwNP, and CRSsNP. A polygenic risk score (PRS) was constructed to evaluate the joint effect of air pollution and genetic predisposition on the development of CRS.
RESULTS: We found that the risk of CRS increased under long-term exposure to PM2.5 [the hazard ratios (HRs) with 95 % CIs: 1.59 (1.26-2.01)], PM10 [1.64 (1.26-2.12)], NO2 [1.11 (1.04-1.17)], and NOx [1.18 (1.12-1.25)], respectively. These effects were more pronounced among participants with CRSwNP, although the differences were not statistically significant. Additionally, we found that the risks for CRS and CRSwNP increased in a graded manner among participants with higher PRS or higher exposure to PM2.5, PM10, or NOx concentrations. However, no multiplicative or additive interactions were observed.
CONCLUSIONS: Long-term exposure to air pollution increases the risk of CRS, particularly CRSwNP underscoring the need to prioritize clean air initiatives and environmental regulations.
Background and Aim: Obstructive sleep apnoea (OSA) is a prevalent sleep-related breathing disorder. OSA is associated with daytime sleepiness, impaired quality of life, and adverse cardiovascular outcome. OSA can be effectively treated with nocturnal continuous positive airway pressure (CPAP) that restores normal breathing during sleep by preventing upper airway collapse. However, many patients in whom treatment of OSA is indicated are not able to adhere to CPAP, and the consequences of untreated OSA seem to differ between OSA phenotypes. Therefore, treatment alternatives to CPAP and a better understanding of treatment implications in different phenotypes of OSA are important targets in this research field. Thus, effective and controlled study designs are needed to address these research questions. Conventional randomised controlled CPAP trials are limited by low CPAP adherence resulting in an underestimation of the treatment effect. In addition, the impracticability of withholding an effective treatment from symptomatic patients resulting in inclusion of less symptomatic and patients with less severe OSA has limited the conclusions from previous trials. The CPAP therapy withdrawal model was introduced to allow studying the pathophysiological consequences of OSA and treatment effects of CPAP in an effective and controlled way. Optimally treated patients previously diagnosed with OSA established on CPAP therapy are included and undergo a short-term therapy interruption. A therapy withdrawal results in recurrence of OSA and pathophysiological changes can be attributed to OSA in this controlled model. However, it is uncertain whether the consequences of OSA during a short-term CPAP therapy withdrawal are comparable to long-term consequences of untreated OSA.

The aim of this two-phase interventional trial is to assess the effects of intermediate and long-term CPAP therapy as well as acute CPAP therapy withdrawal resulting in OSA recurrence compared to longstanding untreated OSA on cardiovascular and symptom outcomes in moderate and severe OSA. The objective is to study the comparability of conventional CPAP therapy trials with the CPAP withdrawal model in terms of evaluating relevant cardiovascular and patient-centred outcomes in OSA.

The investigators hypothesise that the treatment effect of CPAP in previously treatment-naïve patients with OSA - if adherent to CPAP - will support the same conclusions on OSA pathophysiology and therapy effects as a short-term CPAP withdrawal in treatment-adherent patients having a recurrence of OSA in response to CPAP withdrawal and thus support the use of this effective CPAP withdrawal model to use as future study design in interventional trials in OSA. It is hypothesised that the CPAP withdrawal is non-inferior to conventional CPAP trials in studying the effect on blood pressure and OSA-symptoms.
Between 1, July 2018 and 31, Dec 2018, consecutive individuals with metabolic syndrome hyperuricemia are candidates of the present study. After the eligible candidates sign the informed consent, they will receive blood tests with a fasting time of 8 hours at least. The investigators will randomize the study participants by pre-specified random codes with a 1:1:1 ratio to the three groups. The study medication, febuxostat or benzbromarone, will be administered orally on the next day after transthoracic echocardiography is performed. The control group will only receive dietary control. All participant will receive transthoracic echocardiography and blood tests at baseline and at 3 months. The visit will be scheduled at baseline and at the 3rd month. The blood tests include high-sensitivity C-reactive protein, high-sensitivity interleukin-1 beta, high-sensitivity interleukin-6, tumor necrosis factor alpha, Dickkopf-related protein 3, galectin-3, ST2, fibroblast growth factor 23, xanthine oxidase activity, and thioredoxin.
PROBLEM TO BE SOLVED: To obtain the subject growth agent, capable of intentionally growing a skeletal cell and excellent in biocompatibility by including acidic mucopolysaccharides (salt). SOLUTION: This skeletal muscle growth agent comprises acidic mucopolysaccharides (salt). The acidic mucopolysaccharides are preferably an artificially sulfated sulfate, further preferably polysulfate. Sulfate having sulfuric acid group in a ratio of average 0.55-5 molecule per monosaccharide is preferably used as the sulfate. Mucopolysaccharides (salt) has about 1,000-10,000,000 average molecular weight and includes chondroitin sulfate D, chondroitin sulfate E or keratan polysulfuric acid. The effect of the agent is recognized at a dose of 1 μg/kg weight.  Sulfation treatment of polysaccharide is carried out by preparing ice-chilled solvent (e.g. pyridine) in an amount of 10-30 ml per g of polysaccharide which is a raw material, adding sulfating agent (e.g. chlorosulfonic acid) in an amount of 2-6 g based on 1 g raw material polysaccharide thereto, adding 1 g raw material polysaccharide to the solution and reacting polysaccharide with sulfating agent at 0-100 deg.C for 1 hr.
BACKGROUND AND AIMS: The gut microbe-derived metabolite trimethylamine-N-oxide (TMAO) has been implicated in the development of cardiovascular fibrosis. Endoplasmic reticulum (ER) stress occurs after the dysfunction of ER and its structure. The three signals PERK/ATF-4, IRE-1α/XBP-1s and ATF6 are activated upon ER stress. Recent reports have suggested that the activation of PERK/ATF-4 and IRE-1α/XBP-1s signaling contributes to cardiovascular fibrosis. However, whether TMAO mediates aortic valve fibrosis by activating PERK/ATF-4 and IRE-1α/XBP-1s signaling remains unclear.
METHODS: Human aortic valve interstitial cells (AVICs) were isolated from aortic valve leaflets. PERK IRE-1α, ATF-4, XBP-1s and CHOP expression, and production of collagen Ⅰ and TGF-β1 were analyzed following treatment with TMAO. The role of PERK/ATF-4 and IRE-1α/XBP-1s signaling pathways in TMAO-induced fibrotic formation was determined using inhibitors and small interfering RNA.
RESULTS: Diseased valves produced greater levels of ATF-4, XBP-1, collagen Ⅰ and TGF-β1. Interestingly, diseased cells exhibited augmented PERK/ATF-4 and IRE-1α/XBP-1s activation after TMAO stimulation. Inhibition and silencing of PERK/ATF-4 and IRE-1α/XBP-1s each resulted in enhanced suppression of TMAO-induced fibrogenic activity in diseased cells. Mice treated with dietary choline supplementation had substantially increased TMAO levels and aortic valve fibrosis, which were reduced by 3,3-dimethyl-1-butanol (DMB, an inhibitor of trimethylamine formation) treatment. Moreover, a high-choline and high-fat diet remodeled the gut microbiota in mice.
CONCLUSIONS: TMAO promoted aortic valve fibrosis through activation of PERK/ATF-4 and IRE-1α/XBP-1s signaling pathways in vitro and in vivo. Modulation of diet, gut microbiota, TMAO, PERK/ATF-4 and IRE1-α/XBP-1s may be a promising approach to prevent aortic valve fibrosis.
The present disclosure relates to polynucleotide nanostructures and techniques that use polynucleotide nanostructures as bimolecular recognition entities for detecting viral infections, e.g. Covid-19, and other diseases. For example, an artificial biopolymer complex can include a network of polynucleotides including structural units connected to one another via a series of arms and junctions, e.g. in the form of a DNA Star. Intersections of three or more arms form the junctions at a predetermined distance from one another. The artificial biopolymer complex further includes binders, e.g. aptamers, attached to the network of polynucleotides that can bind to antigens of a target analyte. The binders are attached at loci on one or more of the arms forming the junctions. The loci are separated by predetermined inter¬ binder distances such that the binders are positioned on the network of polynucleotides in a predetermined two-dimensional or three- dimensional spatial pattern that matches a two-dimensional or three- dimensional spatial pattern of the antigens on the target analyte. The nucleic acid oligonucleotides, e.g. the aptamers, from which the nanostructure is formed may be labelled with fluorophores and/or quenchers to detect the binding to a target.
The present invention relates to a method for preparing porous microcapsules through the expansion of microcapsules caused by a difference in osmotic pressure between a stock solution and microcapsules, and semi-permeable microcapsules obtained thereby. According to the present invention, it is possible to form pores in microcapsules by using osmotic pressure generated by a difference in concentration and to control the sizes and the number of the pores by adjusting the difference in osmotic pressure or incubating time. Thus, it is possible to obtain porous microcapsules by using various types of polymers or monomers, particularly by using polymers, such as soluble polymers of self-assembled polymers, which require no process of dissolution and separation and allow a simple and cost-efficient process. The microcapsules according to the present invention allow selective permeation of a target material alone to avoid a need for a pretreatment process of a sample, and prevent contamination of internal metal particles so that they may be suitable for sensors for surface-enhanced Raman scattering labeling. The microcapsules according to the present invention are not present in the form of a substrate but are present in the form of microgel (particles), and thus enable injection and mixing to increase the conjugation rate with a target material. In addition, the microcapsules according to the present invention have a simple structure in which metal nanoparticles are supported, and thus are prepared with ease and are amenable to mass production.
PA has beneficial effects on physical, psychological, and social health, and its regular practice helps to prevent numerous chronic diseases. During pregnancy, PA also has many benefits for women's physical condition, weight gain, gestational hypertension, lower back and pelvic pain, and postpartum depressive symptoms and may also reduce fetal macrosomia and positively affect neurogenesis, language development, memory, and other learning-associated cognitive functions. (CNSF 2021). PA is thus recommended to all pregnant women for 150 to 180 minutes a week, adapted to their health status, physical condition, and course of pregnancy. It is also recommended that women limit their Sedentary Behaviour (SB) (to ≤7 waking h/day) during pregnancy.

No French study has assessed the impact of a PA program during pregnancy, and no published study has proposed videoconference PA sessions during pregnancy. Pregnant women's adherence to PA is a limiting factor found in many interventional studies. Possible changes in maternal behavior in practicing PA and reducing SB during pregnancy could also favorably affect the health of mother and child and thus subsequent PA. Given PA's many benefits and SB's harmful effects during pregnancy, assessing programs that enable pregnant women to both increase PA levels and reduce SB seems pertinent and valuable.
Tyvaso DPI (treprostinil) inhalation powder is available as 16 mcg, 32 mcg, 48 mcg, 64 mcg, or 80 mcg of treprostinil in single-dose plastic cartridges with approximate fill weights of 1.6 mg, 3.2 mg, 4.8 mg, 6.4 mg, or 8.0 mg of Tyvaso DPI, respectively. Four cartridges are contained in a single cavity of a blister strip. A card contains 7 blister strips separated by perforations for a total of 28 cartridges of each labeled strength in Titration and Maintenance Kits. For convenience, the perforation allows users to remove a single blister strip containing 4 cartridges. The Institutional Kits contain 4 blister strips for a total of 16 cartridges of each labeled strength.

The cartridges are color-coded, purple for 16 mcg, dark blue for 32 mcg, light blue for 48 mcg, light green for 64 mcg, and orange for 80 mcg. Each cartridge is marked with "Tyvaso DPI" and the corresponding dosage strength of "16 mcg", "32 mcg", "48 mcg", "64 mcg", or "80 mcg".

The Tyvaso DPI Inhaler is individually packaged in a clear overwrap. The inhaler is fully assembled with a removable mouthpiece cover. The Tyvaso DPI Inhaler can be used for up to 7 days from the date of first use. After 7 days of use, the inhaler must be discarded and replaced with a new inhaler.

Tyvaso DPI is available in the following configurations:

Blister Storage:

Inhaler Storage:

Store at 2°C to 25°C (36°F to 77°F); excursions permitted. The Tyvaso DPI Inhaler may be stored refrigerated but should be at room temperature for 10 minutes before use. The inhaler can be used for up to 7 days from the date of first use. After 7 days of use, the inhaler must be discarded and replaced with a new inhaler.

Handling:

If refrigerated, cartridges and inhaler should be at room temperature for 10 minutes before use.
<P>PROBLEM TO BE SOLVED: To automatically create, conformance statement without time and effort.  <P>SOLUTION: The communication data for the communication between a server 1 and a client 2 is taken by online communication. The communication data that has been taken is analyzed to acquire an adaptive range for DICOM standard between the server 1 and the client 2. The adaptive range for DICOM standard between the server 1 and the client 2 is recorded and outputted as a document for a conformance statement. The data preserved in a media 5 is taken in by offline communication. The data that has been taken in is analyzed to acquire an adaptive range for DICOM standard of the media 5. The adaptive range for DICOM standard of the media 5 is recorded and outputted as a document of conformance statement.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE:To increase an apparent hair volume with high durability sustaining the hair-tonic and hair-growing effect by using a combination of a blood circulation accelerator with an organic solvent and a specific fatty acid or its salt. CONSTITUTION:This hair-tonic and hair-growing agent comprises a blood circulation accelerator, an organic solvent (particularly ethanol, or a combination thereof with another organic solvent), a 12-40C straight or branched alkyl or alkenyl fatty acid or its salt. This agent has preferably a pH of 2-11. Further, it is preferred that an organic acid or its salt is admixed. The fatty acid is, for example, lauric acid, tridecanoic acid, myristic acid or the like. The organic acid is citric acid or glycolic acid or the like. This hair-tonic and hair-growing agent can develop blood circulation acceleration effect to suppress depilation and progress of the depilation stage. In addition to this effect, the fatty acid or its salt can give low elastic hairs elasticity and stiffness and develop an action to increase the apparent hair volume.